Loading...
Mechanism-based drug combinations with the DNA-strand-breaking nucleoside analog, CNDAC
CNDAC (2’-C-cyano-2’-deoxy-1-β-D-arabino-pentofuranosyl-cytosine, DFP10917) and its orally bioavailable prodrug, sapacitabine, are undergoing clinical trials for hematological malignancies and solid tumors. The unique action mechanism of inducing DNA strand breaks distinguishes CNDAC from other deox...
Saved in:
| Published in: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5050117/ https://ncbi.nlm.nih.gov/pubmed/27474148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0801 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|